Adimmune Corp., the Taiwanese drug maker, reported August 27th that it has started the first phase of human trials for its experimental COVID-19 vaccine. In addition, Phase 2 is likely to follow in November if everything goes well. In announcing the news, Adimmune Chairman Chan Chi-hsien said he hopes to see people in Taiwan receive their vaccine shots sometime after the middle of 2021.
According to Adimmune, the first stage of the human trials is being supervised by National Taiwan University Hospital professor Chang Shan-chwen and involves about 70 healthy participants aged between 20 and 60.
Taiwan’s Food and Drug Administration (FDA) will closely monitor and review the results of the clinical tests to determine if the following two phases can proceed accordingly, the company said, adding that Phase 2 is likely to take place around November if initial trials are successful.
Getting Other Countries Involved
The plan is to complete the experimental vaccine tests on 3,000 participants by the Lunar New Year before launching Phase 3, which Adimmune said it hopes to conduct in concert with research centers from other countries.
The Taichung-based company said it retains the intellectual property rights to its entire COVID-19 vaccine development process and therefore will not be constrained by any other third party manufacturers or countries. According to Adimmune, so far Brazil, Turkey, the Czech Republic, Singapore, Vietnam and the Philippines have expressed interest in working with the company to produce its COVID-19 vaccine in future.